Darolutamide
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-DAROLUTAMIDE |
|---|---|
| Type | Drug |
| Aliases | NubeqaДаролутамід |
| Status | pending_clinical_signoff |
| Diseases | DIS-PROSTATE |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Drug Facts
| Class | Androgen receptor pathway inhibitor (ARPI) |
|---|---|
| Mechanism | AR antagonist with minimal CNS penetration (low blood-brain-barrier crossing) — favorable cognitive / fall profile vs enzalutamide. Approved for nmCRPC (ARAMIS) and mHSPC (ARASENS, in combination with docetaxel). |
| Typical dosing | 600 mg PO twice daily with food. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Best safety profile of the ARPIs (no excess seizures, falls, cognitive AEs). Preferred for nmCRPC in elderly. ARASENS triplet (ADT + darolutamide + docetaxel) standard for high-volume mHSPC where infrastructure permits.
Used By
Regimens
REG-ADT-DAROLUTAMIDE-DOCETAXEL- ADT + darolutamide + docetaxel (ARASENS triplet)